Functional complementation of the essential gene fabG1 of Mycobacterium tuberculosis by Mycobacterium smegmatis fabG but not Escherichia coli fabG

Journal of Bacteriology

Volumn 189, Issue 10, 2007, Pages 3721-3728

  Parish, Tanya ^a   Roberts, Gretta ^a,e   Laval, Francoise ^b   Schaeffer, Merrill ^c,f   Daffé, Mamadou ^b   Duncan, Ken ^d,g  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^c GLAXOSMITHKLINE   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

^e ST MARY S HOSPITAL   (United Kingdom)

^f BOEHRINGER INGELHEIM VETMEDICA INC   (United States)

^g BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; FABG PROTEIN; FABG1 PROTEIN; MYCOLIC ACID; PROTEIN; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL CHROMOSOME; CELL MEMBRANE PERMEABILITY; ENZYME REPLACEMENT; ESCHERICHIA COLI; ESSENTIAL GENE; FATTY ACID SYNTHESIS; GENE ACTIVITY; GENE DELETION; GENETIC COMPLEMENTATION; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPECIES;

ALCOHOL OXIDOREDUCTASES; AMINO ACID SEQUENCE; ESCHERICHIA COLI; GENETIC COMPLEMENTATION TEST; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; MYCOLIC ACIDS; PHENOTYPE; SPECIES SPECIFICITY;

ESCHERICHIA COLI; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS;

EID: 34248364296     PISSN: 00219193     EISSN: None     Source Type: Journal    
DOI: 10.1128/JB.01740-06     Document Type: Article

References (34)

1. Banerjee, A., M. Sugantino, J. C. Sacchettini, and W. R. Jacobs. 1998. The mabA gene from the inhA operon of Mycobacterium tuberculosis encodes a 3-ketoacyl reductase that fails to confer isoniazid resistance. Microbiology 144:2697-2704.
2. Betts, J. C., A. McLaren, M. G. Lennon, F. M. Kelly, P. T. Lukey, S. J. Blakemore, and K. Duncan. 2003. Signature gene expression profiles discriminate between isoniazid-, thiolactomycin-, and triclosan-treated Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47:2903-2913.
3. Bhakta, S., G. S. Besra, A. M. Upton, T. Parish, C. Sholto-Douglas-Vernon, K. J. C. Gibson, S. Knutton, S. Gordon, R. P. daSilva, M. C. Anderton, and E. Sim. 2004. Arylamine N-acetyltransferase is required for synthesis of mycolic acids and complex lipids in Mycobacterium bovis BCG and represents a novel drug target. J. Exp. Med. 199:1191-1199.
4. Bhatt, A., L. Kremer, A. Z. Dai, J. C. Sacchettini, and W. R. Jacobs. 2005. Conditional depletion of KasA, a key enzyme of mycolic acid biosynthesis, leads to mycobacterial cell lysis. J. Bacteriol. 187:7596-7606.
5. Brennan, P. J. 2003. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis 83:91-97.
6. Camus, J. C., M. J. Pryor, C. Medigue, and S. T. Cole. 2002. Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology 148:2967-2973.
7. Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S. V. Gordon, K. Eiglmeier, S. Gas, C. E. Barry, F. Tekaia, K. Badcock, D. Basham, D. Brown, T. Chillingworth, R. Connor, R. Davies, K. Devlin, T. Feltwell, S. Gentles, N. Hamlin, S. Holroyd, T. Hornby, K. Jagels, A. Krogh, J. McLean, S. Moule, L. Murphy, K. Oliver, J. Osborne, M. A. Quail, M. A. Rajandream, J. Rogers, S. Rutter, K. Seeger, J. Skelton, R. Squares, S. Squares, J. E. Sulston, K. Taylor, S. Whitehead, and B. G. Barrell. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-544.
8. Daffe, M., and P. Draper. 1998. The envelope layers of mycobacteria with reference to their pathogenicity. Adv. Microb. Physiol. 39:131-203.
9. Daffe, M., M.-A. Lanéelle, C. Asselineau, V. Lévy-Frébault, and H. L. David. 1983. Intérêt taxonomique des acides gras des Mycobactéries: proposition d'une méthode d'analyse. Ann. Microbiol. Inst. Pasteur 134:241-256.
10. Daffé, M., M.-A. Lanéelle, and P. L. Valero-Guillen. 1988. Tetraenoic and pentaenoic mycolic acids from Mycobacterium thamnopheos. Structure, taxonomic and biosynthetic implications. Eur. J. Biochem. 177:339-344.
11. Ducasse-Cabanot, S., M. Cohen-Gonsaud, H. Marrakchi, M. Nguyen, D. Zerbib, J. Bernadou, M. Daffe, G. Labesse, and A. Quemard. 2004. In vitro inhibition of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein reductase MabA by isoniazid. Antimicrob. Agents Chemother. 48:242-249.
12. Hayashi, T., O. Yamamoto, H. Sasaki, H. okazaki, and A. Kawaguchi. 1984. Inhibition of fatty acid synthesis by the antibiotic thiolactomycin. J. Antibiot. 37:1456-1461.
13. Heym, B., P. M. Alzari, N. Honore, and S. T. Cole. 1995. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol. Microbiol. 15:235-245.
14. Jackson, M., C. Raynaud, M. A. Laneelle, C. Guilhot, C. LaurentWinter, D. Ensergueix, B. Gicquel, and M. Daffe. 1999. Inactivation of the antigen 85C gene profoundly affects the mycolate content and alters the permeability of the Mycobacterium tuberculosis cell envelope. Mol. Microbiol. 31:1573-1587.
15. Kremer, L., J. D. Douglas, A. Baulard, C. Morehouse, M. R. Guy, D. Alland, L. G. Dover, J. H. Lakey, W. R. Jacobs, P. J. Brennan, D. E. Minnikin, and G. S. Besra. 2000. Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis. J. Biol. Chem. 275:16857-16864.
16. Lai, C.-Y., and J. E. Cronan. 2004. Isolation and characterization of β-ketoacyl-acyl carrier protein reductase (fabG) mutants of Escherichia coli and Salmonella enterica serovar Typhimurium. J. Bacteriol. 186:1869-1878.
17. Laval, F., M. A. Laneelle, C. Deon, B. Monsarrat, and M. Daffe. 2001. Accurate molecular mass determination of mycolic acids by MALDI-TOF mass spectrometry. Anal. Chem. 73:4537-4544.
18. Liu, J., and H. Nikaido. 1999. A mutant of Mycobacterium smegmatis defective in the biosynthesis of mycolic acids accumulates meromycolates. Proc. Natl. Acad. Sci. USA 96:4011-4016.
19. Mahenthiralingam, E., B. I. Marklund, L. A. Brooks, D. A. Smith, G. J. Bancroft, and R. W. Stokes. 1998. Site-directed mutagenesis of the 19-kilodalton lipoprotein antigen reveals no essential role for the protein in the growth and virulence of Mycobacterium intracellulare. Infect. Immun. 66:3626-3634.
20. Marrakchi, H., S. Ducasse, G. Labesse, H. Montrozier, E. Margeat, L. Emorine, X. Charpentier, M. Daffe, and A. Quemard. 2002. MabA (FabG1), a Mycobacterium tuberculosis protein involved in the long-chain fatty acid elongation system FAS-II. Microbiology 148:951-960.
21. Parikh, S. L., G. Xiao, and P. J. Tonge. 2000. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry 39:7645-7650.
22. Parish, T., M. Schaeffer, G. Roberts, and K. Duncan. 2005. HemZ is essential for the growth of Mycobacterium tuberculosis. Tuberculosis 85:197-204.
23. Parish, T., and N. G. Stoker. 2000. Use of a flexible cassette method to generate a double unmarked Mycobacterium tuberculosis tlyA plcABC mutant by gene replacement. Microbiology 146:1969-1975.
24. Pashley, C. A., and T. Parish. 2003. Efficient switching of mycobacteriophage L5-based integrating plasmids in Mycobacterium tuberculosis. FEMS Microbiol. Lett. 229:211-215.
25. Sassetti, C. M., D. H. Boyd, and E. J. Rubin. 2003. Genes required for mycobacterial growth defined by high density mutagenesis. Mol. Microbiol. 48:77-84.
26. Schaeffer, M. L., G. Agnihotri, C. Volker, H. Kallender, P. J. Brennan, and J. T. Lonsdale. 2001. Purification and biochemical characterization of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthases KasA and KasB. J. Biol. Chem. 276:47029-47037.
27. Slayden, R. A., R. E. Lee, J. W. Armour, A. M. Cooper, I. M. Orme, P. J. Brennan, and G. S. Besra. 1996. Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis. Antimicrob. Agents Chemother. 40:2813-2819.
28. Stover, C. K., V. F. Delacruz, T. R. Fuerst, J. E. Burlein, L. A. Benson, L. T. Bennett, G. P. Bansal, J. F. Young, M. H. Lee, G. F. Hatfull, S. B. Snapper, R. G. Barletta, W. R. Jacobs, and B. R. Bloom. 1991. New use of BCG for recombinant vaccines. Nature 351:456-460.
29. Takayama, K., C. Wang, and G. S. Besra. 2005. Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis. Clin. Microbiol. Rev. 18:81-101.
30. Veyron-Churlet, R., O. Guerrini, L. Mourey, M. Daffe, and D. Zerbib. 2004. Protein-protein interactions within the fatty acid synthase-II system of Mycobacterium tuberculosis are essential for mycobacterial viability. Mol. Microbiol. 54:1161-1172.
31. Vilcheze, C., H. R. Morbidoni, T. R. Weisbrod, H. Iwamoto, M. Kuo, J. C. Sacchettini, and W. R. Jacobs. 2000. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis. J. Bacteriol. 182:4059-4067.
32. Wong, M. Y. H., P. A. Steck, and G. R. Gray. 1979. The major mycolic acids of Mycobacterium smegmatis. J. Biol. Chem. 5734-5740.
33. Zhang, Y., T. Garbe, and D. Young. 1993. Transformation with katG restores isoniazid-sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations. Mol. Microbiol. 8:521-524.
34. Zhang, Y., and D. Young. 1994. Strain variation in the katG region of Mycobacterium tuberculosis. Mol. Microbiol. 14:301-308.